Mimetogen Pharmaceuticals Inc. ("Mimetogen"),
a privately held drug development company, announced today that it has successfully
completed a Series A equity financing led by Boston-based VIMAC Milestone Medica
Fund with MSBi Capital returning as a co-investor. The Company has also completed
negotiations with McGill University, Montréal for the exclusive worldwide
rights to develop and commercialize novel technologies and therapeutics in the
areas of cancer and glaucoma.